Clinical Trial: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07575399) titled 'Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)' on May 04.

Brief Summary: Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Study Start Date: May 25

Study Type: INTERVENTIONAL

Condition: Obesity or Overweight

Intervention: DRUG: Maridebart Cafraglutide

Maridebart cafraglutide will be administered via subcutaneous (SC) injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Amgen

Published by HT Digital Content S...